Showing results (1341-1350 of 1,523) with videos related to
Sort By:
Pageof 153
Cancer Immunology, Immunotherapy : CII|October 20, 2021
Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II studyJin-Ji Yang, Cheng Huang, Yun Fan, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2023
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA TrialThomas John, Christian Grohé, Jonathan W Goldman, et al.ACS Omega|October 13, 2025
Identification of a G Protein-Coupled Receptor for Buccalin-Type Peptides in the Mollusk Aplysia: Evolutionary Insights into Neuropeptide SignalingJu-Ping Xu, Xue-Ying Ding, Qing-Chun Jin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2014
Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylationJin-Ji Yang, Xu-Chao Zhang, Jian Su, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2025
Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung CancerJia-Tao Zhang, Si-Yang Liu, Xuan Gao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2025
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 TrialPasi A Jänne, Bin-Chao Wang, Byoung Chul Cho, et al.NPJ Precision Oncology|September 19, 2022
Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysisChao Zhang, Hua-Fei Chen, Shi Yan, et al.Clinical Lung Cancer|June 6, 2022
Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705)Si-Yang Maggie Liu, Hong-Hong Yan, Xue-Wu Wei, et al.Lung Cancer (Amsterdam, Netherlands)|October 30, 2020
Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective studyJiang-Tao Cheng, Yi-Hui Yao, Yu-Er Gao, et al.The New England Journal of Medicine|June 5, 2023
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLCMasahiro Tsuboi, Roy S Herbst, Thomas John, et al.Pageof 153